Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression
Phase 2
Recruiting
- Conditions
- Locally Advanced Urothelial CarcinomaLocally Advanced Ureter Urothelial CarcinomaMetastatic Renal Pelvis Urothelial CarcinomaRecurrent Renal Pelvis Urothelial CarcinomaRecurrent Ureter Urothelial CarcinomaStage IIIA Bladder Cancer AJCC v8Unresectable Ureter Urothelial CarcinomaUnresectable Urethral Urothelial CarcinomaUnresectable Urothelial CarcinomaLocally Advanced Bladder Urothelial Carcinoma
- Interventions
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT04953104
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
Phase 2
Recruiting
- Conditions
- Prostate CarcinomaStage III Prostate Cancer AJCC v8Stage IIC Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IIIA Prostate Cancer AJCC v8Stage IIIB Prostate Cancer AJCC v8Stage IIIC Prostate Cancer AJCC v8
- Interventions
- Drug: Antiandrogen TherapyDrug: Abiraterone AcetateDrug: ApalutamideProcedure: BiopsyRadiation: Radiation TherapyDrug: NiraparibDrug: Prednisone
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT04947254
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
Phase 2
Active, not recruiting
- Conditions
- Resectable Pancreatic AdenocarcinomaStage IB Pancreatic Cancer AJCC v8Stage IIA Pancreatic Cancer AJCC v8Stage IIB Pancreatic Cancer AJCC v8Borderline Resectable Pancreatic AdenocarcinomaStage IA Pancreatic Cancer AJCC v8
- Interventions
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT04940286
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
Phase 2
Active, not recruiting
- Conditions
- Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Ureter Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic MelanomaMetastatic Renal Pelvis Urothelial CarcinomaMetastatic Ureter Urothelial CarcinomaPathologic Stage IIID Cutaneous Melanoma AJCC v8Stage III Urethral Cancer AJCC v8Locally Advanced Bladder CarcinomaLocally Advanced Renal Pelvis Urothelial Carcinoma
- Interventions
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT04940299
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia
Phase 1
Active, not recruiting
- Conditions
- Refractory Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Interventions
- Drug: Gemtuzumab OzogamicinDrug: Liposome-encapsulated Daunorubicin-Cytarabine
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT04915612
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer
Recruiting
- Conditions
- Lung Non-Small Cell Carcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bronchoscopy with Bronchoalveolar LavageOther: ChemoradiotherapyProcedure: Computed TomographyOther: Diagnostic Laboratory Biomarker AnalysisDrug: Immune Checkpoint InhibitorProcedure: Nasal Wash and CollectionOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationProcedure: Spirometry
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 150
- Registration Number
- NCT04913311
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Effect of Materials for Subcuticular Suture (Quill vs. Monocryl) on Complications After Liver Resection
Recruiting
- Conditions
- Liver and Intrahepatic Bile Duct Neoplasm
- Interventions
- Other: Electronic Health Record Review
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04906174
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
Phase 2
Active, not recruiting
- Conditions
- Metastatic Clear Cell Renal Cell CarcinomaAdvanced Clear Cell Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v8
- Interventions
- Biological: NivolumabOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationDrug: Sitravatinib
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 88
- Registration Number
- NCT04904302
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Indiana University Hospital / IU Simon Cancer Center, Indianapolis, Indiana, United States
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
Phase 1
Active, not recruiting
- Conditions
- Clinical Stage IV Merkel Cell Carcinoma AJCC v8Advanced Bladder CarcinomaClinical Stage III Cutaneous Melanoma AJCC v8Pathologic Stage IIIA Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8Stage III Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Bladder Cancer AJCC v8Stage IV Lung Cancer AJCC v8Advanced Lung Non-Small Cell Carcinoma
- Interventions
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT04902040
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
Phase 2
Recruiting
- Conditions
- Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Non-Small Cell Cancer AJCC v7Stage IIIA Lung Non-Small Cell Cancer AJCC v7Stage IIIB Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8Stage III Lung Non-Small Cell Cancer AJCC v7Stage IIIC Lung Cancer AJCC v8
- Interventions
- Biological: DurvalumabDrug: CarboplatinProcedure: Local Consolidation TherapyOther: Quality-of-Life AssessmentDrug: GemcitabineOther: Questionnaire AdministrationDrug: Nab-paclitaxelDrug: PaclitaxelDrug: Pemetrexed
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT04892953
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath